Development of small-molecule Trypanosoma brucei N-myristoyltransferase inhibitors: discovery and optimisation of a novel binding mode

Daniel Spinks, Victoria Smith, Stephen Thompson, David A. Robinson, Torsten Luksch, Alasdair Smith, Leah S. Torrie, Stuart McElroy, Laste Stojanovski, Suzanne Norval, Iain T. Collie, Irene Hallyburton, Bhavya Rao, Stephen Brand, Ruth Brenk, Julie A. Frearson, Kevin D. Read, Paul G. Wyatt, Ian H. Gilbert

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The enzyme N-myristoyltransferase (NMT) from Trypanosoma brucei has been validated both chemically and biologically as a potential drug target for human African trypanosomiasis. We previously reported the development of some very potent compounds based around a pyrazole sulfonamide series, derived from a high-throughput screen. Herein we describe work around thiazolidinone and benzomorpholine scaffolds that were also identified in the screen. An X-ray crystal structure of the thiazolidinone hit in Leishmania major NMT showed the compound bound in the previously reported active site, utilising a novel binding mode. This provides potential for further optimisation. The benzomorpholinone was also found to bind in a similar region. Using an X-ray crystallography/structure-based design approach, the benzomorpholinone series was further optimised, increasing activity against T. brucei NMT by >1000-fold. A series of trypanocidal compounds were identified with suitable in vitro DMPK properties, including CNS exposure for further development. Further work is required to increase selectivity over the human NMT isoform and activity against T. brucei. HATs off to diversity! Screening a diverse library against Trypanosoma brucei N-myristoyltransferase (NMT) identified hits based on thiazolidinone and benzomorpholine scaffolds. X-ray crystallography of these compounds bound to Leishmania major NMT revealed novel active site binding conformations. Using the structural information, the benzomorpholine scaffold was optimised to a blood-brain barrier penetrant compound with activity against TbNMT of <0.002 μm.

Original languageEnglish
Pages (from-to)1821-1836
Number of pages16
JournalChemMedChem
Volume10
Issue number11
DOIs
Publication statusPublished - Nov 2015

Fingerprint

Trypanosoma brucei brucei
Molecules
Scaffolds
Leishmania major
X ray crystallography
X Ray Crystallography
Catalytic Domain
African Trypanosomiasis
Sulfonamides
Blood-Brain Barrier
Libraries
Conformations
glycylpeptide N-tetradecanoyltransferase
Screening
Protein Isoforms
Crystal structure
Binding Sites
Throughput
X-Rays
X rays

Keywords

  • Human African trypanosomiasis (HAT)
  • Medicinal chemistry
  • N-myristoyltransferase
  • Structure-based drug design
  • Trypanosoma brucei

Cite this

Spinks, Daniel ; Smith, Victoria ; Thompson, Stephen ; Robinson, David A. ; Luksch, Torsten ; Smith, Alasdair ; Torrie, Leah S. ; McElroy, Stuart ; Stojanovski, Laste ; Norval, Suzanne ; Collie, Iain T. ; Hallyburton, Irene ; Rao, Bhavya ; Brand, Stephen ; Brenk, Ruth ; Frearson, Julie A. ; Read, Kevin D. ; Wyatt, Paul G. ; Gilbert, Ian H. / Development of small-molecule Trypanosoma brucei N-myristoyltransferase inhibitors : discovery and optimisation of a novel binding mode. In: ChemMedChem. 2015 ; Vol. 10, No. 11. pp. 1821-1836.
@article{16375a05f33842178b2bedd773a4f328,
title = "Development of small-molecule Trypanosoma brucei N-myristoyltransferase inhibitors: discovery and optimisation of a novel binding mode",
abstract = "The enzyme N-myristoyltransferase (NMT) from Trypanosoma brucei has been validated both chemically and biologically as a potential drug target for human African trypanosomiasis. We previously reported the development of some very potent compounds based around a pyrazole sulfonamide series, derived from a high-throughput screen. Herein we describe work around thiazolidinone and benzomorpholine scaffolds that were also identified in the screen. An X-ray crystal structure of the thiazolidinone hit in Leishmania major NMT showed the compound bound in the previously reported active site, utilising a novel binding mode. This provides potential for further optimisation. The benzomorpholinone was also found to bind in a similar region. Using an X-ray crystallography/structure-based design approach, the benzomorpholinone series was further optimised, increasing activity against T. brucei NMT by >1000-fold. A series of trypanocidal compounds were identified with suitable in vitro DMPK properties, including CNS exposure for further development. Further work is required to increase selectivity over the human NMT isoform and activity against T. brucei. HATs off to diversity! Screening a diverse library against Trypanosoma brucei N-myristoyltransferase (NMT) identified hits based on thiazolidinone and benzomorpholine scaffolds. X-ray crystallography of these compounds bound to Leishmania major NMT revealed novel active site binding conformations. Using the structural information, the benzomorpholine scaffold was optimised to a blood-brain barrier penetrant compound with activity against TbNMT of <0.002 μm.",
keywords = "Human African trypanosomiasis (HAT), Medicinal chemistry, N-myristoyltransferase, Structure-based drug design, Trypanosoma brucei",
author = "Daniel Spinks and Victoria Smith and Stephen Thompson and Robinson, {David A.} and Torsten Luksch and Alasdair Smith and Torrie, {Leah S.} and Stuart McElroy and Laste Stojanovski and Suzanne Norval and Collie, {Iain T.} and Irene Hallyburton and Bhavya Rao and Stephen Brand and Ruth Brenk and Frearson, {Julie A.} and Read, {Kevin D.} and Wyatt, {Paul G.} and Gilbert, {Ian H.}",
year = "2015",
month = "11",
doi = "10.1002/cmdc.201500301",
language = "English",
volume = "10",
pages = "1821--1836",
journal = "ChemMedChem",
issn = "1860-7179",
publisher = "Wiley-VCH",
number = "11",

}

Development of small-molecule Trypanosoma brucei N-myristoyltransferase inhibitors : discovery and optimisation of a novel binding mode. / Spinks, Daniel; Smith, Victoria; Thompson, Stephen; Robinson, David A.; Luksch, Torsten; Smith, Alasdair; Torrie, Leah S.; McElroy, Stuart; Stojanovski, Laste; Norval, Suzanne; Collie, Iain T.; Hallyburton, Irene; Rao, Bhavya; Brand, Stephen; Brenk, Ruth; Frearson, Julie A.; Read, Kevin D.; Wyatt, Paul G.; Gilbert, Ian H.

In: ChemMedChem, Vol. 10, No. 11, 11.2015, p. 1821-1836.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Development of small-molecule Trypanosoma brucei N-myristoyltransferase inhibitors

T2 - discovery and optimisation of a novel binding mode

AU - Spinks, Daniel

AU - Smith, Victoria

AU - Thompson, Stephen

AU - Robinson, David A.

AU - Luksch, Torsten

AU - Smith, Alasdair

AU - Torrie, Leah S.

AU - McElroy, Stuart

AU - Stojanovski, Laste

AU - Norval, Suzanne

AU - Collie, Iain T.

AU - Hallyburton, Irene

AU - Rao, Bhavya

AU - Brand, Stephen

AU - Brenk, Ruth

AU - Frearson, Julie A.

AU - Read, Kevin D.

AU - Wyatt, Paul G.

AU - Gilbert, Ian H.

PY - 2015/11

Y1 - 2015/11

N2 - The enzyme N-myristoyltransferase (NMT) from Trypanosoma brucei has been validated both chemically and biologically as a potential drug target for human African trypanosomiasis. We previously reported the development of some very potent compounds based around a pyrazole sulfonamide series, derived from a high-throughput screen. Herein we describe work around thiazolidinone and benzomorpholine scaffolds that were also identified in the screen. An X-ray crystal structure of the thiazolidinone hit in Leishmania major NMT showed the compound bound in the previously reported active site, utilising a novel binding mode. This provides potential for further optimisation. The benzomorpholinone was also found to bind in a similar region. Using an X-ray crystallography/structure-based design approach, the benzomorpholinone series was further optimised, increasing activity against T. brucei NMT by >1000-fold. A series of trypanocidal compounds were identified with suitable in vitro DMPK properties, including CNS exposure for further development. Further work is required to increase selectivity over the human NMT isoform and activity against T. brucei. HATs off to diversity! Screening a diverse library against Trypanosoma brucei N-myristoyltransferase (NMT) identified hits based on thiazolidinone and benzomorpholine scaffolds. X-ray crystallography of these compounds bound to Leishmania major NMT revealed novel active site binding conformations. Using the structural information, the benzomorpholine scaffold was optimised to a blood-brain barrier penetrant compound with activity against TbNMT of <0.002 μm.

AB - The enzyme N-myristoyltransferase (NMT) from Trypanosoma brucei has been validated both chemically and biologically as a potential drug target for human African trypanosomiasis. We previously reported the development of some very potent compounds based around a pyrazole sulfonamide series, derived from a high-throughput screen. Herein we describe work around thiazolidinone and benzomorpholine scaffolds that were also identified in the screen. An X-ray crystal structure of the thiazolidinone hit in Leishmania major NMT showed the compound bound in the previously reported active site, utilising a novel binding mode. This provides potential for further optimisation. The benzomorpholinone was also found to bind in a similar region. Using an X-ray crystallography/structure-based design approach, the benzomorpholinone series was further optimised, increasing activity against T. brucei NMT by >1000-fold. A series of trypanocidal compounds were identified with suitable in vitro DMPK properties, including CNS exposure for further development. Further work is required to increase selectivity over the human NMT isoform and activity against T. brucei. HATs off to diversity! Screening a diverse library against Trypanosoma brucei N-myristoyltransferase (NMT) identified hits based on thiazolidinone and benzomorpholine scaffolds. X-ray crystallography of these compounds bound to Leishmania major NMT revealed novel active site binding conformations. Using the structural information, the benzomorpholine scaffold was optimised to a blood-brain barrier penetrant compound with activity against TbNMT of <0.002 μm.

KW - Human African trypanosomiasis (HAT)

KW - Medicinal chemistry

KW - N-myristoyltransferase

KW - Structure-based drug design

KW - Trypanosoma brucei

UR - http://www.scopus.com/inward/record.url?scp=84946085197&partnerID=8YFLogxK

U2 - 10.1002/cmdc.201500301

DO - 10.1002/cmdc.201500301

M3 - Article

C2 - 26395087

AN - SCOPUS:84946085197

VL - 10

SP - 1821

EP - 1836

JO - ChemMedChem

JF - ChemMedChem

SN - 1860-7179

IS - 11

ER -